Brief: TCR2 Therapeutics Announces Collaboration With Cell And Gene Therapy Catapult For The Manufacturing Of Its Novel T Cell Therapies For Cancer
26/03/2019 11:24
March 26 (Reuters) - Tcr2 Therapeutics Inc TCRR.O :
* TCR2 THERAPEUTICS ANNOUNCES COLLABORATION WITH CELL AND
GENE
THERAPY CATAPULT FOR THE MANUFACTURING OF ITS NOVEL T CELL
THERAPIES FOR CANCER
Source text for Eikon: ID:nPn9FJrxQa
Further company coverage: TCRR.O
(((Reuters.Briefs@thomsonreuters.com);;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview